DB17855InvestigationalGene Therapies
AAV1-FS344 is an investigational gene therapy developed by Milo Biotechnology to deliver follistatin, a potent myostatin inhibitor. It is being investigated for the treatment of Duchenne Muscular Dystrophy, Becker Muscular...
- Also known as
- AAV1-Follistatin · rAAV1 CMV huFollistatin 344 · rAAV1-Follistatin · rAAV1.CMV.huFollistin344
- Code names
- AAV1-FS344
What you can answer from here — as of April 23, 2025
Which companies are running trials of AAV1-FS344, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account